Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. (Q33735589)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Payam Nahid

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Charles M. Heilig

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

16

Eric L Nuermberger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Susan E Dorman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Radojka M Savic

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Stefan Goldberg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Neil Schluger

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Grace Muzanyi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

John L Johnson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Emily J Hecker

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Lorna Bozeman

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Pei-Jean I Feng

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ruth N Moro

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

William MacKenzie

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kelly E Dooley

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Andrew Vernon

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Marc Weiner

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Tuberculosis Trials Consortium

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

English

0 references

publication date

1 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Respiratory and Critical Care Medicine

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

191

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

333-343

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

A four-month gatifloxacin-containing regimen for treating tuberculosis

24 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Exact and Asymptotic Weighted Logrank Tests for Interval Censored Data: The interval R package.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Role of individual drugs in the chemotherapy of tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Two-sided confidence intervals for the single proportion: comparison of seven methods

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

A non-parametric test for interval-censored failure time data with application to AIDS studies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Bacteriologic basis of short-course chemotherapy for tuberculosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

The early bactericidal activity of drugs in patients with pulmonary tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis

21 June 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1843OC

Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1843OC

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1843OC

Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1843OC

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1843OC

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1843OC

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1843OC

Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447287

Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis

30 October 2018

1 reference

12 December 2020

Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis

1 reference

12 December 2020

Single and multiple dose pharmacokinetics of rifapentine in man: part II

1 reference

12 December 2020

A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association

1 reference

12 December 2020

Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: The results up to 24 months

1 reference

12 December 2020

10.1164/RCCM.201410-1843OC

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25489785%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference